KPV

• Molecular Formula: Ac-C16H32N4O6-NH2
• Molecular Weight: 378.47 g/mol
• Sequence: Lys-Pro-Val

DESCRIPTION

KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of α -melanocyte stimulating hormone ( α -MSH). α -MSH stimulates the production and release of melanin by melanocytes in skin and hair, acting through melanocortin 1 receptor. Several studies have previously shown that KPV has decreased inflammation and tumorigenesis in the body. The KPV anti-inflammatory effect is PepT1-mediated in intestinal epithelial and immune cells. PepT1 is an oligopeptide transporter that is overexpressed in the in the colonic epithelial cells of chronic ulcerative colitis, which can deliver KPV into cytosol in the intestine. The tripeptide, KPV has significant antimicrobial and anti-inflammatory properties especially in those with psoriasis. Psoriasis is a chronic autoimmune condition which causes the rapid build-up of skin cells and is usually treated using hydrocortisone. In people with psoriasis, KPV has shown to limit symptoms of the condition including itchiness, dryness, redness, peeling, and more. Therefore, KPV could be used for an extended period of time without risking the unwanted complications of long term steroid therapy. KPV is a promising, therapeutic treatment for inflammatory bowel disease (IBD), colon cancer, and inflammatory skin disorders, in particular, psoriasis.

PROTOCOL

• Content & Potency: 30ml TopiClick at 15mg/ml
• Suggested dosage: 0.5ml applied to area twice daily

CLINICAL RESEARCH

Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Anti Inflammatory and ProtectiveEffects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases

Alpha-MSH is a tridecapeptide derived from proopiomelanocortin. Many studies over the last few years have provided evidence That Alpha -MSH has potent protective and antiinflammatory effects. These effects can be elicited via centrally expressed melanocortin receptors that orchestrate descending neuro-genic antiinflammatory pathways. Alpha-MSH can also exert antiinflammatory and protective effects on cells of the immune system and on peripheral nonimmune cell types expressing melanocortin receptors. At the molecular level, Alpha-MSH affects various pathways implicated in regulation of inflammation and protection, i.e., nuclear factor-B activation, expression of adhesion molecules and chemokine receptors, produc – tion of proinflammatory cytokines and mediators, IL-10 synthesis, T cell proliferation and activity, inflammatory cell migration, expression of antioxidative enzymes, and apoptosis. The antiinflammatory effects of -MSH have been validated in animal models of experimentally induced fever; irritant and allergic contact dermatitis, vasculitis, and fibrosis; ocular, gastrointestinal, brain, and allergic airway inflammation; and arthritis, but also in models of organ injury. One obstacle limiting the use of alpha-MSH in inflammatory disorders is its pigmentary effect. Due to its preserved antiinflammatory effect but lack of pigmentary action, the C-terminal tripeptide of -MSH, KPV, has been delineated as an alternative for antiinflammatory therapy. KdPT, a derivative of KPV corresponding to amino acids 193–195 of IL-1, is also emerging as a tripeptide with antiinflammatory effects. The physicochemical properties and expected low costs of production render both agents suitable for the future treatment of immune-mediated inflammatory skin and bowel disease, fibrosis, allergic and inflammatory lung disease, ocular inflammation, and arthritis.

Here are some URLs where you can find information about peptide KPV:

• Research articles: Many research articles have been published that mention peptide KPV, particularly in the context of its potential therapeutic uses. PubMed is a good resource for searching for relevant articles: https://pubmed.ncbi.nlm.nih.gov/.

I hope this helps you find the information you’re looking for!